SCHIZOFY 30MG TAB

60.00 EGP

30 mg of aripiprazole .

SCHIZOFY 30MG TAB; aripiprazole, antipsychotics .

ACTIVE-INGREDIENT OF SCHIZOFY 30MG TAB

30 mg of aripiprazole .

INDICATION OF SCHIZOFY 30MG TAB

schizophrenia shizofy is indicated for the treatment schizophrenia . The efficacy of shizofy was established in four 4-6 week trials in adults and one 6- week trial in adolescents ( 13-17 years ) maintainence efficacy was demonstarated in one trial in adults and adults and can and be extrapolated to pediatric patients (10-17 years ) . adjunctive therapy : shizofy is indicated as an adjunctive therapy to either lithium or valproate for the acute treatment of manic and mixed epidoes associated with bipolar 1 disorder . efficacy was established in one 6 – week adjunctive trial in adults and can be extrapolated to pediatric patients ( 10-17 years ) . adjunctive treatment of major depressive disorder : shizofy is indicated for the treatment of irriability associated with autistic disorder . efficacy was established in two 8-week trials in pediatric patients ( aged 6 to 17 years ) with irritability associated in with autistic disorder ( including symptoms of aggression towards others , deliberate self-injuriousness , temper tantrums , and quickly changing moods . special considerations in treating pediatric schizophrenia , bipolar i disorder , and irritability associated with auistic disorder . psychiatric disorders in childen and adolsecents are often serious mental disorders with variable symptoms profiles that are not always congrunt with adult diagnostic criteria . it is recommended that psychotropic medication therapy for pediatric patients only be initiated after a through diagnostic evaluation has been conducted and careful consideration given to the risks associated with medication treatment . medication treatment for pediatric patients with schizophrenia , bipolar 1 disorder , and irritability associated with autistic disorder is indicated as part of a total treatment program that often includes psychological , educational , and social interventions .

DOSAGE OF SCHIZOFY 30MG TAB

Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet

Ask your pharmacist or doctor for help if you do not understand the instructions on the box .

The recommended dose is : –

schizophrenia : usual dose : the recommended starting dose for shizofy is 10 mg /day or 15 mg/day administered on a once -a – day shedule without regard to meals . Shizofy has been systematically evaluated and shown to be effective in a dose range of 10 mg/day to 30 mg/day , when administerated as the the tablet formulation ; however , doses higher than 10 mg /day or 15 mg/day were not more effective than 10 mg /day or 15 mg/day . dosage increases should generally not be made before 2 weeks , the time needed to achieve steady – state . dose in special populations : dosage adjustments are not routinely indicated on the basis of age , gender , race , or renal or hepatic impairment status . dosage adjustment for patients taking aripiprazole concomitantly with potential CYP3A4 inhibitors: when concomitant administration of ketoconazole with aripiprazole occurs , aripiprazole dose should be reduced to one – half of the usual dose . when the CYP3A4 inhibitor is withdraw from the combination therapy , aripiprazole dose should then be increased . dosage adjustment for patients taking aripiprazole dose should then be increased . dosage adjustment for patients taking aripiprazole concomitantly with potential CYP2D6 inhibitors : when concomitant administration of potential CYP2D6 inhibitors such as quinidine fluxetine or paroxetine with aripiprazole occurs aripiprazole dose should be reduced at least therapy , aripiprazole dose should then be increased . dosage adjustment for patients taking potential CYP3A4 inducer : when a potential CYP3A4 inducer such as carbamazepine is add to aripiprazole therapy the aripiprazole dose should be doubled ( to 20 or 30 mg ) additional dose icreases should be based on clinically evaluation . when carbamazepine is withdrwan from the combination therapy , the aripiprazole dose should be reduced to 10 to 15 mg . maintenance therapy : while there is no body evidence available to answer the question of how long a patient treated with aripiprazole should remain on it , systematic evaluation of patients with schizophreniawho had been symptomatically stable on the other antipsychotic medications for periods of 3 months or longer were discontinued from those medications , and were there administrated schizofy 15 mg /day and observed for replase during a period of up to 26 weeks , demonstrated a benefit of such maintenance treatment patients should be periodically reassessed to determine the need for maintenance treatment . switching from other antipsychotic : there are no systematically collected data to specifically address switching patients with schizophrenia from other antipsychotic to schizofy or concerning concomitant administration with other antipsychotic . while immediate discontinuation of the previous antipsychotic treatment may be acceptable for some patients with schizophrenia more gradual discontinuation may be most appropriate for others . in all cases , the period of overlapping antipsychotic administration should be minimized . bipolar disorder : usual dose : in clinical trails , the starting dose was 30 mg given once of a day . a dose of 30 mg/day was found to be effective when administration as the tablet formulation . approximately 15 % of patients had their dose decreased to 15 mg based on assessment of tolerability . the safety of doses above 30 mg /day has been evaluated in clinical trials . maintenance therapy : while there is no body of evidence to answer the question of how long a patient treated with aripiprazole should remain on it . patients with bipolar disorder who had been symptomatically stable on schizofy tablets ( 15 mg / day with a starting dose of 30 mg/day ) for at least 6 consecutive weeks and then randomized to schizofy tablets 15 mg /day or 30 mg /day ) or placebo and monitored for relapse , demonstrated a benefit of such maintenance treatment while it is generally agreed that pharmacological treatment beyond an acute response in mania is desirable , both for maintenance of the initial response and for prevention of new mania episodes there are no systematically obtained data to support the use of aripiprazole in such longer-term treatment (i.e., beyond 6 weeks ) . animal toxicology : aripiprazole produced retinal degeneration in albino rats in a 26- week chronic toxicity study at a dose of 60 mg /kg and in a 2-year carcinogenicity study at doses of 40 and 60 mg/kg . the 40 – and 60 – mg /kg doses are 13 and 19 times the maximum recommended human dose (MRHD) based on mg /m2 and 7 to 14 times human exposure at MRHD based on AUC . evaluation of the retinas of albino mice and monkeys did not reveal evidence of retinal degeneration . additional studies to further evaluated the mechanism have not been performed . the relevance of this finding to human risk is unknown .

OVER-DOSAGE OF SCHIZOFY 30MG TAB

medDRA terminology has been used to classify the adverse reactions . Human experience a total of 76 cases of deliberate or accidental overdosage with oral aripiprazole have been reported worldwide . These include overdosage with oral alone and in combination with other substances . no fatality was reported from these cases . of the 44 cases with known outcome , 33 cases recovered without sequele and one case recovered a known outcome involved 1080 mg of oral aripiprazole (36 times the maximum recommended daily dose ) in a patient who fully recovered , induced in the 76 cases are 10 cases of delibratetions up of 195 mg with no fetaliyies . common adverse reactions ( reported in at least 5% overdose cases ) reported with oral aripiprazole overdosage ( alone or in combination with other substances 0 include vomiting , somnolence , and tremor . other clinically important signs and symptoms observed in one or more patients with aripiprazole overdoses ( alone or with other substances ) include acidosis , aggression , aspartate aminotransferase increased , atrial fibrillation , bradycardia , coma , confusional state , convulsion , blood creatine phosphokinase increased , depressed level of conschiousness , hypertension , hypokalemia , hypotension , lethargy , loss of consciousness , QRS complex prolonged , pneumonia aspiration , respiratory arrest , status epilepticus , and tachycardia . management of overdosage : no specific information is available on the treatment of overdose with aripiprazole . an electrocardiogram should be obtained in case of overdosage and if QT interval prolongation is present , cardiac monitoring should be instituted , otherwise , management of overdose should be concentrate on supportive therapy , maintaining an adequate airway , oxygenation and ventilation , and management of symptoms . close medical supervision and monitoring should be continue until the patient recovers . charcoal : in the event of an overdose of shizofy , an early administration may be useful in partially preventing the absorption pf aripiprazole . administration of 50 g activated charcoal , one hour after a sigle 15 mg oral dose of aripiprazole , decreased the mean AUC and cmax of aripiprazole by 50% . hemodialysis : although there is no information on the effect of hemodialysis in treating an overdose with aripiprazole , hemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins .

CONTRA-INDICATION OF SCHIZOFY 30MG TAB

hypersensitivity to the active substance or to any excipients .

STORAGE OF SCHIZOFY 30MG TAB

store at temp not exceeding 30 C , in a dry place . Keep out of reach of children .
PACK OF SCHIZOFY 30MG TAB
carton box of one (AL/PVC )” strips each of 10 film coated tablets & an inner leaflet .
SCHIZOFY 30MG TAB MANUFACTURED BY
WESTERN PHARMACEUTICALINDUSTRIES

https://www.drugs.com/search.php?searchterm=aripiprazole&a=1

https://www.webmd.com/drugs/2/drug-64437-4274/aripiprazole-oral/aripiprazole-oral/details

https://www.gardeniapharmacy.com/category/medicine-2/

Form

Gender

How to use

Reviews

There are no reviews yet.

Show reviews in all languages (1)

Be the first to review “SCHIZOFY 30MG TAB”

Your email address will not be published. Required fields are marked *

Shopping Cart
Don`t copy text!
Scroll to Top
Open chat